Your browser doesn't support javascript.
loading
Expression of mutant Asxl1 perturbs hematopoiesis and promotes susceptibility to leukemic transformation.
Nagase, Reina; Inoue, Daichi; Pastore, Alessandro; Fujino, Takeshi; Hou, Hsin-An; Yamasaki, Norimasa; Goyama, Susumu; Saika, Makoto; Kanai, Akinori; Sera, Yasuyuki; Horikawa, Sayuri; Ota, Yasunori; Asada, Shuhei; Hayashi, Yasutaka; Kawabata, Kimihito Cojin; Takeda, Reina; Tien, Hwei-Fang; Honda, Hiroaki; Abdel-Wahab, Omar; Kitamura, Toshio.
Affiliation
  • Nagase R; Division of Cellular Therapy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Inoue D; Division of Cellular Therapy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan inoued@mskcc.org.
  • Pastore A; Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY.
  • Fujino T; Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY.
  • Hou HA; Division of Cellular Therapy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Yamasaki N; Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
  • Goyama S; Department of Disease Model, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
  • Saika M; Division of Cellular Therapy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Kanai A; Division of Cellular Therapy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Sera Y; Department of Molecular Oncology and Leukemia Program Project, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
  • Horikawa S; Department of Disease Model, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
  • Ota Y; Division of Cellular Therapy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Asada S; Department of Pathology, Research Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Hayashi Y; Division of Cellular Therapy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Kawabata KC; Division of Cellular Therapy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Takeda R; Division of Cellular Therapy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Tien HF; Division of Cellular Therapy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Honda H; Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
  • Abdel-Wahab O; Department of Disease Model, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
  • Kitamura T; Field of Human Disease Models, Major in Advanced Life Sciences and Medicine, Tokyo Women's Medical University, Tokyo, Japan.
J Exp Med ; 215(6): 1729-1747, 2018 06 04.
Article in En | MEDLINE | ID: mdl-29643185
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Repressor Proteins / Leukemia / Cell Transformation, Neoplastic / Hematopoiesis / Mutation Type of study: Prognostic_studies Limits: Adult / Animals / Humans Language: En Journal: J Exp Med Year: 2018 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Repressor Proteins / Leukemia / Cell Transformation, Neoplastic / Hematopoiesis / Mutation Type of study: Prognostic_studies Limits: Adult / Animals / Humans Language: En Journal: J Exp Med Year: 2018 Document type: Article Affiliation country: Country of publication: